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Abstract
The spread of carbapenemase producers in Enterobacteriaceae has now been identiﬁed worldwide. Three main carbapenemases have been
reported; they belong to three classes of b-lactamases, which are KPC, NDM, and OXA-48. The main reservoirs of KPC are Klebsiella
pneumoniae in the USA, Israel, Greece, and Italy, those of NDM are K. pneumoniae and Escherichia coli in the Indian subcontinent, and those of
OXA-48 are K. pneumoniae and Escherichia coli in North Africa and Turkey. KPC producers have been mostly identiﬁed among nosocomial
isolates, whereas NDM and OXA-48 producers are both nosocomial and community-acquired pathogens. Control of their spread is still
possible in hospital settings, and relies on the use of rapid diagnostic techniques and the strict implemention of hygiene measures.
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Introduction
Although they were rarely reported a decade ago, carbape-
nemase-producing Enterobacteriaceae are now being extensively
reported. Different groups of enzymes possessing carbape-
nemase properties have emerged, and are spreading worldwide.
Some of these enzymes hydrolyse carbapenems very efﬁciently,
whereas others show weak activity against carbapenems. Some
include broad-spectrum cephalosporins in their hydrolytic
pattern, and some do not. Some have activity that may be
inhibited (at least partially) by b-lactamase inhibitors (such as
clavulanic acid and tazobactam), whereas most are not inhibited
by clinically available inhibitors. However, these signiﬁcant
differences do not really explain the successful spread of speciﬁc
enzymes in speciﬁc countries or areas [1].
The main features related to the epidemiology of these
enzymes are as follows:
1. The ﬁrst parameter is the primary reservoir. Indeed, it is very
likely that a speciﬁc enzymewill emerge in a given geographical
area where many favourable conditions exist, such as a
high-density population, poor hygiene, and high selective
pressure linked to overuse and misuse of antibiotics.
2. The second parameter concerns the genetics of the
carbapenemase gene, as some genetic structures are prone
to enhance gene plasticity and mobility. Some integron or
transposon structures and plasmids may indeed favour
horizontal gene transfer. Some plasmids possess a broad
host range for replication, and can therefore enhance
interspecies dissemination, whereas some others possess a
narrow host range. Some plasmids replicate very efﬁciently
and are self-conjugative, whereas others are not self-con-
jugative or conjugate at very low rate. The genetic
background of the strain harbouring the carbapenemase
gene may also play an important role, as the emergence of
one gene in a so-called successful clone (being, for instance,
more likely to disseminate from patient to patient, or more
able to survive on dry surfaces) can favour the initial spread
of a carbapenemase through the spread of the correspond-
ing bacterial host.
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3. The third main parameter concerns the level of human
population exchanges once a reservoir has been constituted.
If the emergence of a carbapenemase occurs in a geograph-
ical area where the population is mobile (an important
worldwide-located diaspora, tourism, or medical tourism),
then the likelihood of seeing that resistance determinant
emerging worldwide is high.
The spread of carbapenemase genes is explained by a
combination of these three parameters. Among the four
molecular classes according to the Ambler classiﬁcation [2],
carbapenemases can be found in classes A, B, and D.
The Class A Carbapenem-hydrolysing
b-lactamases
The ﬁrst carbapenemase (NmcA; non-metallo-carbapenemase
of class A) was identiﬁed >20 years ago in an Enterobacter
cloacae isolate. Since then, the SME enzymes (Serratia marces-
cens enzymes) have been identiﬁed in S. marcescens. This family
includes ﬁve variants (SME-1 to SME-5), all of which are
chromosomally encoded [3] and have been recovered spo-
radically throughout the USA and Canada [4–6] (M. Mulvey,
unpublished). The IMI enzymes (imipenem-hydrolysing b-lac-
tamases) have been detected in rare isolates of Enterobacter in
the USA [7], France [8], Croatia [9], Finland [10], and
Argentina[11], and, more recently, a colistin-resistant Enterob-
acter asburiae isolate was recovered in Ireland [12]. The genes
encoding these carbapenemases are mostly chromosomally
located and associated with AmpC-type regulation
(LysR-dependent), limiting their spread and their expression
at a high level. However, genes encoding the IMI-2 variant have
been found to be plasmid-located in environmental E. asburiae
strains recovered from several US rivers [13] and in a single
E. cloacae isolate in China [14].
The ﬁrst variant of the GES family (for ‘Guiana
extended-spectrum b-lactamase’), i.e. GES-1, which is not a
carbapenemase, was reported in 2000. The GES family now
includes 24 variants (http://www.lahey.org/Studies/other.asp#
table 1) [15]. All GES variants possess the ability to hydrolyse
broad-spectrum cephalosporins, but, as a result of speciﬁc
amino acid substitutions inside the active site, extension of
their spectrum of activity towards carbapenems has been
identiﬁed for several variants [16]. Among these variants, GES-
2, GES-4, GES-5, GES-6, GES-11, GES-14 and GES-18 hydro-
lyse imipenem efﬁciently [17]. Although they are quite rare,
GES enzymes have been identiﬁed worldwide. Among those
GES variants for which signiﬁcant carbapenemase activity has
been noted are the following: GES-2 identiﬁed in Pseudomonas
aeruginosa, with one clone being the cause of a nosocomial
outbreak in South Africa [18]; and GES-5 identiﬁed in
Enterobacteriaceae and P. aeruginosa, which has been widely
reported in South America (Brazil) [19,20], and for which
there are some scattered reports in Turkey [21] and South
Korea [22]. GES-11 and GES-14 have been identiﬁed only in
Acinetobacter baumannii [23], and GES-18 has been identiﬁed in
P. aeruginosa but not in Enterobacteriaceae [24].
It is noteworthy that this GES-5 variant possessing signif-
icant carbapenemase activity has disseminated quite widely,
being found not only in nosocomial settings but also in the
environment in South America [25], and being the main
carbapenem-hydrolysing GES-type enzyme identiﬁed in Entero-
bacteriaceae. The high rate of GES-5 producers in South
America and, in particular, in Brazil [26] might be a
consequence of the occurrence of the non-carbapenemase
GES-1 variant in the same geographical area [27]. It might be
speculated that selective pressure resulting from the use of
carbapenems has resulted in the emergence of GES-5.
KPC enzymes (Klebsiella pneumoniae carbapenemases) are
currently the most clinically signiﬁcant enzymes among the
class A carbapenemases. They have been mainly identiﬁed in
K. pneumoniae, which is an important nosocomial pathogen, and
confer high levels of resistance not only to carbapenems but also
to most b-lactams, including broad-spectrum cephalosporins.
The ﬁrst KPC producer (a KPC-2-positive K. pneumoniae) was
identiﬁed in 1996 on the eastern coast of the USA [28], and since
then a series of variants have been identiﬁed, even thoughKPC-2
remains the most commonly identiﬁed variant. There are now
19 KPC variants, all being point-mutant derivatives of a common
amino acid sequence.Within a few years, KPC producers spread
globally andwere identiﬁed inmanyGram-negative species, even
though KPC enzymes have been mostly identiﬁed in K. pneu-
moniae [29] (Fig. 1). In Latin America, KPC producers are
endemic in some areas, such as in Colombia and Argentina [29].
Some reports have also shown the occurrence of KPC
producers in Puerto Rico and Mexico [30,31] (Fig. 1).
In Europe, KPC producers have been found almost
everywhere, mostly being being linked to importation from
endemic areas [29]. Those endemic areas in Europe are
Greece and Italy, and probably Poland, where nosocomial
outbreaks caused by KPC-producing K. pneumoniae often
occur [32]. In Israel, endemicity of KPC producers has been
demonstrated by many studies, with a large number of
nosocomial reports, but also, noticeably, some cases occurring
in the community [29,33].
The extent of the diffusion of KPC in Southeast Asia is not
well known, even though China is considered to be a country
where some areas are facing endemic situations [29]. In India,
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there are very few reports on KPC-producing isolates, the
most commonly identiﬁed carbapenemases being NDM and
OXA-48-like enzymes (see below). However, there are some
reports showing that KPC producers are occurring in India
[34,35].
It is noteworthy that one speciﬁc KPC-2-producing or
KPC-3-producing K. pneumoniae clone (sequence type 258)
has been extensively identiﬁed worldwide [36], indicating that
it has signiﬁcantly contributed to the spread of this resistance
trait.
The Class B Metallo-b-lactamases (MBLs)
MBLs, which are known to be intrinsic in many environmental
and opportunistic bacterial species, have been identiﬁed as
acquired enzymes since the early 1990s, either in Pseudomonas
or in Enterobacteriaceae [37]. The most common families of
acquired class B MBLs identiﬁed in Enterobacteriaceae include
the VIM and IMP groups [37], together with the emerging
NDM group (see below), whereas others, such as GIM-1 and
KHM-1, have been found only sporadically [38,39]. Although
they have been reported worldwide, the VIM producers
among Enterobacteriaceae are highly prevalent in the southern
part of Europe and around the Mediterranean Sea (ﬁrst
reported in Italy by Cornaglia et al.), whereas the IMP
producers remain mostly located in Asia [37].
IMP-type b-lactamases were the ﬁrst acquired MBLs to be
identiﬁed, and have been detected in a series of clinically
important Gram-negative bacilli, such as Enterobacteriaceae,
Pseudomonas, and Acinetobacter. Among Enterobacteriaceae,
IMP-1 was found in an S. marcescens isolate in Japan in 1991
[40]. So far, 48 IMP variants have been assigned, and IMP-type
carbapenemase producers have spread worldwide. However,
the frequency of IMP-producing isolates worldwide is much
less than that of KPC, VIM, NDM or OXA-48 producers. The
wide spread of IMP-type enzymes has been demonstrated
mainly in Japan, Taiwan, and eastern China, although there are
single reports from many other countries, and isolates
producing these enzymes have sometimes caused nosocomial
outbreaks. Another type of MBL corresponds to the VIM-type
enzymes (Verona integron-encoded MBLs). VIM-1 was ﬁrst
identiﬁed in Italy in 1997 [41,42], and VIM-2 was then reported
in France in a P. aeruginosa isolate dating from 1996 [43].
Currently, the VIM family includes 41 variants, which have
been mainly identiﬁed in P. aeruginosa but also in enterobac-
terial isolates. VIM-2 is actually the most commonly reported
MBL worldwide [1], with endemic spread in southern Europe
(Greece, Spain, and Italy) and Southeast Asia (South Korea and
Taiwan), but has also caused outbreaks in Africa, in particular
in the Ivory Coast [44], South Africa [45], Tunisia [46], and
some European countries, such as Germany [47], The
Netherlands [48], and France [49,50]. These outbreaks have
mainly involved VIM-producing P. aeruginosa, and rarely
enterobacterial species. In Europe, Greece is known to be
endemic for VIM-1-producing Enterobacteriaceae. Many Greek
studies have reported the spread of VIM-1-producing K. pneu-
moniae at a national level, but this enzyme has also been
identiﬁed in Escherichia coli, Citrobacter freundii, Morganella
morganii, Serratia species, and Klebsiella oxytoca [51,52].
Recently, the KHM-1 b-lactamase was identiﬁed in Japan in a
single C. freundii clinical isolate that had been recovered in
1997 [39]. The GIM-1 MBL (which stands for ‘German
imipenemase’), which was ﬁrst identiﬁed in a P. aeruginosa
isolate from Germany [38], has since been identiﬁed in other
P. aeruginosa isolates [53], and also in S. marcescens [54],
E. cloacae [55], and Acinetobacter pittii [56]. Worringly, GIM-1
was recently identiﬁed in many enterobacterial species,
Unknown distribution of KPC producers
Sporadic spread of KPC producers
Outbreaks caused by KPC producers
Endemicity of KPC producers 
FIG. 1. Geographical distribution of KPC
producers.
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including Escherichia coli, C. freundii, and K. oxytoca, always in
Germany [53]. The other described acquired MBLs include
SPM-1 [57], SIM-1 [58], DIM-1 [59], TMB-1 [60], and AIM-1
[61], but they have not been identiﬁed in Enterobacteriaceae,
being found either in Pseudomonas or Acinetobacter.
One of the most most clinically signiﬁcant carbapenemase is
NDM-1 (New Delhi metallo-b-lactamase), which was
described in 2009, the corresponding K. pneumoniae and
Escherichia coli isolates being from a Swedish patient of Indian
origin hospitalized in €Orebro, Sweden, after a hospital stay in
New Delhi [62,63]. NDM-1 shares very little identity with
other MBLs, the most similar being VIM-1/VIM-2, with only
32.4% amino acid identity. NDM-1 efﬁciently hydrolyses a
broad range of b-lactams, including penicillins, cephalosporins,
and carbapenems, but sparing monobactams such as aztreo-
nam [62]. Since the ﬁrst description of NDM-1, eight variants
of this enzyme have been published (NDM-1 to NDM-8), and
12 have been assigned (http://www.lahey.org); most of them
originated from Asia [64–66]. As compared with NDM-1, the
NDM-4, NDM-5 and NDM-7 variants possess increased
activity towards carbapenems [67–70]. A detailed analysis of
the resistance patterns shows their systematic association with
other antibiotic resistance determinants, such as plasmid-
mediated AmpC cephalosporinases, clavulanic acid-inhibited
expanded-spectrum b-lactamases, other types of carbapene-
mases (OXA-48, VIM and KPC types), and enzymes conferring
broad-spectrum resistance to aminoglycosides (16S RNA
methylases), to quinolones (Qnr), to macrolides (esterases),
to rifampicin (rifampicin-modifying enzymes), to chloramphe-
nicol, and to sulphamethoxazole [71,72]. Consequently, many
of the NDM-1 producers remain susceptible only to colistin,
fosfomycin, and tigecycline [73].
The main identiﬁed reservoir of NDM-producing Entero-
bacteriaceae is the Indian subcontinent (Pakistan, India, and Sri
Lanka) [63] (Fig. 2). The spread of NDM producers has been
extensively identiﬁed not only among patients from the Indian
subcontinent, but also in the soil [74,75]. Therefore, it is likely
that the environment is already heavily contaminated with
NDM producers. The prevalence of carriage is estimated to be
5–15% in that part of the world [76,77]. Signiﬁcant spread of
NDM producers has also been identiﬁed in the UK, which has
close relationships with India and Pakistan [65]. Subsequently,
NDM producers among Enterobacteriaceae have been reported
in almost all of world, including many countries in Asia, Africa,
Australia, the Americas, and Europe [78]. NDM producers are
now on top of the list of carbapenemase producers in
European countries such as the UK and France [63,65].
Other particularly important sources of NDM producers
(or established secondary reservoirs) are the Balkan states
[79,80], the Arabian peninsula [81,82], and North African
countries [64]. The impact of intercontinental travel as a
source of spread of NDM producers has been extensively
reported. NDM producers have been extensively identiﬁed in
countries where many Indians and Pakistanis live, such as
Canada, the USA, the UK, Ireland, South Africa, Saudi Arabia,
the Gulf countries, and Australia. It is noteworthy that the
identiﬁcation of NDM producers is not always associated with
an Indian subcontinental origin, supporting the hypothesis of
established secondary reservoirs [83–87].
All NDM-producing enterobacterial species have been
found to be involved in infections, but K. pneumoniae and
Escherichia coli are the main causes of hospital and commu-
nity-acquired infections, respectively. The frequent identiﬁca-
tion of NDM-producing Escherichia coli is of concern,
considering that Escherichia coli is the main pathogen respon-
sible for urinary tract infections, community-acquired infec-
tions, and diarrhoea [88]. In fact, antibiotic resistance
occurring in community settings is, by deﬁnition, very difﬁcult
to contain, and diarrhoea is the source of further spread of
NDM producers in the environment, at least in Southeast
Asia.
It may therefore be expected that outbreaks caused mostly
by NDM-producing K. pneumoniae will be increasingly
reported worldwide and, concomitantly, a slow but progres-
sive increase in the prevalence rate of NDM-producing
Escherichia coli will be observed, mirroring the spread of
CTX-M producers that we have observed in community
setttings since the 2000s. It is noteworthy that outbreaks
caused by NDM-1-producing Escherichia coli or E. cloacae have
been reported in Bulgaria and Turkey, respectively [89,90].
However, it is difﬁcult to evaluate the time that it will take to
obtain prevalence rates of NDM-producing Escherichia coli
comparable to those observed for CTX-M producers (15–
70%, depending on the countries). Long-term persistence of
NDM producers in the human gut will contribute to further
human-to-human transfer [91], leading to some autochtho-
nous cases in non-endemic areas, as observed in France [92].
The Carbapenem-hydrolysing Class D
b-lactamases (CHDLs)
Class D b-lactamases, which are also named OXAs (for
‘oxacillinases’), now include >400 enzymes, among which only
some variants actually possess carbapenemase activity [93].
With the exception of rare OXA enzymes (such as OXA-163;
see below), the CHDLs do not hydrolyse (or very poorly
hydrolyse) expanded-spectrum cephalosporins. Notably, all
CHDLs possess weak carbapenemase activity, which does not
confer high-level resistance to carbapenems if it is not
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associated with other factors, such as permeability defects
[94].
Although most of the CHDL variants have been identiﬁed in
Acinetobacter, OXA-48 and its derivatives have been identiﬁed
in Enterobacteriaceae [95]. The ﬁrst OXA-48 producer to be
identiﬁed was a K. pneumoniae isolate recovered in Turkey in
2003 [96]. Since then, OXA-48 producers have been exten-
sively reported in Turkey, often being the causes of nosoco-
mial outbreaks [96–99]. OXA-48-producing isolates have now
widely disseminated throughout European countries, and it is
highly probable that one of the main reservoirs, apart from
Turkey, corresponds to North African countries [95]. Indeed,
most countries in the Mediterranean area frequently report
the occurrence of OXA-48-producing Enterobacteriaceae [95].
Hospital outbreaks involving OXA-48-producing K. pneumo-
niae, Escherichia coli and E. cloacae have been reported in many
countries, including France, Germany, Switzerland, Spain, The
Netherlands, and the UK [100–105]. One of the main factors
sustaining the successful spread of the blaOXA-48 gene among a
variety of enterobacterial species is the high transfer efﬁciency
of the plasmid on which blaOXA-48 is located [106]. This
self-conjugative plasmid, which is considered to be epidemic,
does not carry any additional resistance determinants, and
conjugates at a very high frequency to any enterobacterial
species [107].
OXA-48-producing isolates have been reported in the
Middle East, in countries such as Lebanon, the Sultanate of
Oman, Saudi Arabia, and Kuwait [108–114] (Fig. 3). In Africa,
they have been mainly identiﬁed in the northern countries
(Morocco, Algeria, Tunisia, Egypt, and Libya) [101,115–126],
but OXA-48 producers have also been identiﬁed in Senegal
and South Africa [127,128] (Fig. 3).
The same OXA-48-producing K. pneumoniae isolate of
sequence type 395 has been identiﬁed in Morocco, France,
and The Netherlands, indicating clonal dissemination in some
instances [101]. It is noteworthy that the recently identiﬁed
occurrence of OXA-48 producers in Israel was demonstrated
to be linked with medical tourism, involving patients who had
been transferred from Georgia or Jordan [129]. Also notice-
able is the fact that OXA-48 is still considered to be almost
completely absent from the Americas, even though recent
reports have shown the emergence of OXA-48-producing
K. pneumoniae in the USA [30].
A point-mutant derivative of OXA-48, namely OXA-181,
sharing the same hydrolytic properties, has been identiﬁed in
enterobacterial isolates from India and from patients with a
link with the Indian subcontinent [130]. The genetic struc-
ture surrounding blaOXA-181 was found to be distinct from
that associated with blaOXA-48, indicating that the current
disseminations are not related to each other. The blaOXA-181
gene has been identiﬁed in different countries, such as
France, the UK, Norway, Romania, the Sultanate of Oman,
Canada, Australia, New Zealand, Singapore, and Sri Lanka,
and a link with India has been systematically observed
[95,128,131].
OXA-204 was recently identiﬁed in a series of K. pneumo-
niae isolates recovered from patients having a link with Algeria
or Tunisia. OXA-204 has two amino acid substitutions as
compared with OXA-48, and preliminary data indicate a
substrate proﬁle that is very similar to that of OXA-48 [132].
OXA-232 has recently been identiﬁed in K. pneumoniae
isolates in France, from patients who had been transferred
from Mauritius or India [133]. It has ﬁve amino acid substi-
tutions as compared with OXA-48, but is just a point-mutant
derivative of OXA-181. OXA-232 possesses a weaker ability
to hydrolyse carbapenems than OXA-48, but was recently
found to be co-associated with NDM-1 in a carbapenem-resis-
tant K. pneumoniae isolate obtained very recently in the USA
from a patient who had been previously identiﬁed in India
[134].
Unknown distribuon of NDM producers
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Outbreaks caused by NDM producers
Endemicity of NDM producers 
FIG. 2. Geographical distribution of
NDM producers.
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Finally, another OXA-48-like enzyme, namely OXA-163,
has been recently identiﬁed in enterobacterial isolates recov-
ered in Argentina [135]. OXA-163 differs from OXA-48 by a
single amino acid substitution and a four amino acid deletion
[95,135]. Interestingly, although its carbapenemase activity is
lower than that of OXA-48, its substrate proﬁle includes
broad-spectrum cephalosporins, and its activity is partially
inhibited by clavulanic acid, thus conferring on the corre-
sponding enterobacterial recipient strains a resistance pheno-
type very similar to that of an expanded-spectrum b-lactamase
producer. OXA-163 was originally identiﬁed in enterobacterial
isolates (E. cloacae and K. pneumoniae) recovered in Argentina
[135], and then in Egypt [136]. Other studies conﬁrmed that
OXA-163 producers were frequently identiﬁed in Argentina
[30], and one single amino acid mutant (OXA-247) sharing the
same hydrolytic properties was identiﬁed in that country
[137].
Conclusion
Although the spread of carbapenemases appears to be quite
recent, the ‘big players’, which are NDM, KPC, and OXA-48,
are now widely distributed. Important reservoirs have been
identiﬁed: the Indian subcontinent for NDM, the USA, Israel,
Greece and Italy for KPC, and Turkey and North Africa for
OXA-48. The Indian subcontinent actually acts as a reservoir
of all three types of carbapenemases: KPC, NDM, and
OXA-181. KPC producers are still mostly identiﬁed in
nosocomial K. pneumoniae isolates. In contrast, NDM and
OXA-48 are being extensively identiﬁed in nosocomial and
community-acquired K. pneumoniae and Escherichia coli isolates,
respectively. Interestingly KPC and NDM have been identiﬁed
in unrelated Gram-negative species, whereas OXA-48 has
been identiﬁed only in enterobacterial species. However,
genetic analysis indicates that the OXA-48 gene has a
propensity to spread among enterobacterial species at a much
higher rate than KPC and NDM genes.
The important reservoirs of these carbapenemase produc-
ers that have been identiﬁed act as signiﬁcant sources for their
dissemination worldwide. Indeed, it is extremely common to
see the occurrence of a carbapenemase-producing isolate in a
geographical area where there is no endemicity or an epidemic
situation linked to a patient who has a previous history of
hospitalization or a travel in an endemic area. This indicates
that very early identiﬁcation of carbapenemase producers, at
least in hospital settings, may contribute to limitating their
spread. The use of rapid diagnostic techniques is key to their
diagnosis, and should be followed by the implementation of
strict hygiene measure to limit their spread.
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